Jeito Capital leads a USD 65 million Series A financing in ReproNovo to advance treatments in reproductive medicine and women's health.

May 21, 2025•7 months ago

Amount Raised

$65 Million

Round Type

series a

LausanneBiotechnologyHealth Care

Investors

Alsa VenturesYsios CapitalM VenturesAxa Im AltsJeito Capital

Description

Jeito Capital is leading a USD 65 million Series A financing round in ReproNovo to support clinical trials for its candidates RPN-001 and RPN-002. This investment highlights Jeito's commitment to innovative biopharma solutions. The funding aims to address growing infertility issues worldwide. Ksenija Pavletic from Jeito will join ReproNovo's Board of Directors.

Company Information

Company

ReproNovo

Location

Lausanne, Vaud, Switzerland

About

ReproNovo is a cutting-edge biopharmaceutical company identifying and developing innovative solutions to address critical gaps in reproductive medicine and women’s health. Our team is composed of proven experts with deep experience in reproductive medicine, drug development, regulatory affairs and business development who have throughout their careers successfully brought multiple therapies to market. Lead clinical compound, RPN-001 (leflutrozole), is initially being developed to treat male infertility. RPN-002 (nolasiban) is a first-in-disease and first-in-class molecular entity to manage adenomyosis and increase the probability of embryo implantation in women undergoing assisted reproductive technology (ART) treatments. Both assets are Phase 2 ready. ReproNovo is financed by Jeito Capital, AXA IM Alts, founding investor M Ventures, Ysios Capital and ALSA Ventures.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends